Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Shows Diabetes Dominance, But Will It Last?

Executive Summary

Lilly's first quarter benefited from rising sales for most of its diabetes products, which has become one of the most difficult therapeutic areas to do business in due to competitive and reimbursement pressures.


Related Content

Finance Watch: Lilly Cuts 3,500 Jobs Globally To Drive Growth
2Q Pharma Results Preview: Lilly, Biogen, Amgen, GSK And Gilead
Considering The Value Of Cardiovascular Data And Real World Evidence In Diabetes
Lilly Preps Abemaciclib To Take On Ibrance; Differentiation Still A Question
Rebates, Pricing Pressure Weigh On J&J's Q1 Pharma Sales
Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA
Cardiovascular Benefits of SGLT2 Inhibitors: A Class Effect?
US Insulin Pricing Probe Clouds Prospects for Novo Nordisk, Others
Where Will It End? Lilly’s US Price Concessions Increase 30% In 2016
BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts